James G. Greger

James G. Greger

Auto-generated profile, based on publicly available information

James G. Greger

Janssen Research & Development, LLC Chesterbrook Pennsylvania USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
XMXuewen Ma
Xuewen Ma
GBGary Borzillo
Gary Borzillo
MKMartine J. Christine Kothe
Martine J. Christine Kothe
MSMadhu Sanga
Madhu Sanga
GCGerald Chu
Gerald Chu
EAEdward Attiyeh
Edward Attiyeh
Janus kinase (JAK) signaling has been implicated in human inflammatory diseases, including psoriasis, rheumatoid arthritis, and inflammatory bowel disease. Lorpucitinib (JNJ‐64251330) is an oral, small molecule, pan‐JAK inhibitor. Unlike systemic JAK antagonists, lorpucitinib was found to have enteric (gut)‐selective properties, providing possible applications in diseases of the human gastrointestinal tract. Here, lorpucitinib was evaluated in a phase I, two‐part, dosing study (NCT04552197) to assess pharmacokinetics, pharmacodynamic biomarkers, and safety in healthy participants. In part 1, 24 participants were randomized to 1 of 4 treatment arms receiving either lorpucitinib (30 mg daily, 30 mg every 12 hours (q12h), or 75 mg q12h) or tofacitinib (5 mg q12h) for 5 days. Part 2 was a food‐effect study in which 12 participants received a single 75‐mg dose of lorpucitinib under either fasting or fed conditions. In part 1, plasma and gut tissue concentrations of lorpucitinib showed approximately dose‐proportional increases. At all doses, lorpucitinib concentrations were significantly higher (392‐ to 1928‐fold) in the gut mucosal biopsies vs. the corresponding plasma samples, demonstrating high enteric selectivity and significantly exceeding both the tissue concentrations (> 200‐fold) and tissue/plasma ratios observed with tofacitinib. JAK inhibition in biopsies was confirmed via reduction in pSTAT‐3 levels. In part 2, lorpucitinib plasma concentrations were detectable but at low levels, with no statistical differences in PK parameters between the fed and fasted groups. Lorpucitinib was safe and well‐tolerated, and the data may be useful in designing studies to evaluate lorpucitinib in patients with JAK/STAT‐driven gastrointestinal diseases.